CRISPR Therapeutics (CRSP) Set to Post Quarterly Earnings on Monday

CRISPR Therapeutics (NASDAQ:CRSP) is anticipated to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect CRISPR Therapeutics to announce earnings of ($1.04) per share and revenue of $14.75 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The firm had revenue of $10.18 million during the quarter. On average, analysts expect CRISPR Therapeutics to post ($4.44) EPS for the current fiscal year and ($3.60) EPS for the next fiscal year.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $51.35 on Monday. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics has a 1 year low of $44.12 and a 1 year high of $64.74. The company has a market cap of $4.96 billion, a PE ratio of -10.91 and a beta of 1.76. The company’s 50-day moving average is $54.19 and its two-hundred day moving average is $52.92.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James Kasinger sold 10,400 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $60.24, for a total value of $626,496.00. Following the completion of the transaction, the general counsel directly owned 94,784 shares in the company, valued at approximately $5,709,788.16. The trade was a 9.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 47,837 shares of the business’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $49.78, for a total value of $2,381,325.86. Following the sale, the chief executive officer owned 311,899 shares in the company, valued at approximately $15,526,332.22. The trade was a 13.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 93,558 shares of company stock worth $4,881,663 in the last ninety days. Company insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday, October 9th. Citizens Jmp restated a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.75.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.